FP602A

FP602A (also known as FP6026) is an innovative CD8 T-cell-based T-cell engager (TCE) being developed by Guangdong Fapon Biopharma for the treatment of various tumors and cancers. Developed using the company's Bi/Tri-TCE technology platform, FP602A is specifically designed to recruit and activate CD8+ cytotoxic T cells against tumor cells. This approach differs from traditional T-cell engagers that typically target CD3 to recruit a broad range of T cells; by focusing on the CD8+ subset, FP602A aims to leverage the potent cytotoxic capabilities of these cells while potentially improving the safety profile. The specific tumor-associated antigen (TAA) targeted by FP602A remains undisclosed by the developer. The drug is currently in the early stages of development as part of Fapon Biopharma's oncology pipeline.